An agreement has been reached between Johnson & Johnson and its Janssen Pharmaceutical firms unit a more than 10 million dollars settlement with Cuyahoga and Summit counties of Ohio regarding the litigation related to opioids, instead of letting the matter reach the federal trial. Following the statement of Mallinckrodt Pharmaceuticals of Staines-Upon-Thames, the announcement was made. It was said by the firm that it had executed a 30 million dollars settlement agreement with Ohio’s Cuyahoga and Summit counties regarding the lawsuits related to opioids. It was scheduled for both firms to face trial in October in the federal, multi-district litigation, alongside other defendants. Johnson & Johnson’s settlement comes after the firm was given an order to pay 572 million dollars for satisfying a litigation judgment related to the opioid crisis in Oklahoma. These lawsuits are amongst the plenty filed across the country against the manufacturers, as well as, distributers of drugs, normally claiming these firms had a role in causing the opioid crisis by committing to deceptive or aggressive marketing, as well as, distribution practices. Johnson & Johnson is still confident that it marketed the widespread release of tapentadol, fentanyl (Duragesic), as well as, tapentadol responsibly and since the launch of those drugs, they had a very minute part played in the opioid crisis i.e. they accounted for less than 1 percent of the overall opioid prescriptions in the US. Johnson & Johnson vended the United States marketing rights for tapentadol four years back and since 2008 it has not done the marketing of fentanyl in the United States. All the Johnson & Johnson, as well as, Janssen Pharmaceutical’s litigation has been resolved because of this week’s settlement agreement with the 2 Ohio counties i.e. Cuyahoga and Summit without the firm having to admit to their claims.
Tags : Johnson & Johnson, Janssen Pharmaceutical firms,